Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 18/20 | 0.67 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
| ▸ | ECE1 | P42892 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554032 | 1.00 | CASP1 (0.67) | CASP1MMEECE1PPARGPPARA | |
| SCHEMBL376886 | 1.00 | CASP1 (0.67) | CASP1MMEECE1PPARGPPARA | |
| SCHEMBL10605640 | 0.94 | PPARA (0.62) | CASP1MMEECE1PPARGPPARA | |
| SCHEMBL10789378 | 0.94 | MME (0.62) | CASP1MMEECE1 | |
| SCHEMBL9069237 | 0.93 | CASP1 (0.60) | CASP1MMEECE1 | |
| SCHEMBL9069236 | 0.92 | CASP1 (0.59) | CASP1MMEECE1PPARGPPARA | |
| SCHEMBL4280669 | 0.91 | CASP1 (0.67) | CASP1 | |
| SCHEMBL4280674 | 0.91 | CASP1 (0.67) | CASP1 | |
| SCHEMBL13589993 | 0.91 | MME (0.65) | MMEECE1 | |
| Tetrylammonium SCHEMBL14988987 | 0.91 | CASP1 (0.58) | CASP1MMEECE1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| CN-119264459-B | Zinc amino acid complex crystal material and preparation method and application thereof | 德州学院 | 2025-03-04 | — | — | CN | claimed |
| CN-119264459-A | Zinc amino acid complex crystal material and preparation method and application thereof | 德州学院 | 2025-01-07 | — | — | CN | claimed |
| CN-112011495-B | Recombinant escherichia coli for expressing thermolysin mutant and application thereof | 江南大学 | 2022-12-16 | — | — | CN | claimed |
| CN-112011494-B | Recombinant escherichia coli and application thereof in synthesis of aspartame through whole-cell transformation | 江南大学 | 2022-12-02 | — | — | CN | claimed |
| WO-2022156189-A1 | USE OF POLYPEPTIDE COMPOUND IN PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND INTESTINAL FIBROSIS RELATED THERETO | 深圳市图微安创科技开发有限公司 | 2022-07-28 | — | — | WO | claimed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | claimed |
| CN-112011495-A | Recombinant escherichia coli for expressing thermolysin mutant and application thereof | 江南大学 | 2020-12-01 | — | — | CN | claimed |
| CN-112011494-A | Recombinant escherichia coli and application thereof in synthesis of aspartame through whole-cell transformation | 江南大学 | 2020-12-01 | — | — | CN | claimed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | claimed |
| US-4570015-A | ACIDIFYING AN ALKALINE AQUEOUS SOLUTION OF THE DIALKALI METAL SALTAT HIGH TWMPWRATURE; PURITY | HATCO CHEMICAL CORPORATION (US) | 1986-02-11 | — | — | US | claimed |
| US-4523026-A | Synthesis of N-benzyloxycarbonyl-L-aspartic acid | HATCO CHEMICAL CORPORATION (US) | 1985-06-11 | — | — | US | claimed |
| US-4521514-A | Process for producing an addition compound of a dipeptide ester and an amino acid ester | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1985-06-04 | — | — | US | claimed |
| US-4518792-A | FROM BENZYL CHLOROFORMATE AND ASPARTIC ACID SALT, SURFACTANT OR BUFFER TO IMPROVE PURITY | HATCO CHEMICAL CORPORATION (US) | 1985-05-21 | — | — | US | claimed |
| US-4508912-A | UNING METAL OXIDE, HYDROXIDE, ACID OR ACID SALT, OR ORGANOBASIC COMPOUND CATALYST | AJINOMOTO COMPANY, INCORPORATED (JP) | 1985-04-02 | — | — | US | claimed |
| EP-0072015-B1 | METHOD FOR PURIFYING N-BENZYLOXYCARBONYL ASPARTIC ACID | PPG INDUSTRIES, INC. (US) | 1984-10-31 | — | — | EP | claimed |
| US-4450284-A | Method for purifying N-benzyloxycarbonyl aspartic acid | PPG INDUSTRIES, INC. (US) | 1984-05-22 | — | — | US | claimed |
| EP-0099585-A1 | Process for producing an addition compound of a dipeptide ester and an amino acid ester | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1984-02-01 | — | — | EP | claimed |
| EP-0072015-A1 | Method for purifying N-benzyloxycarbonyl aspartic acid | PPG INDUSTRIES, INC. (US) | 1983-02-16 | — | — | EP | claimed |
| US-4293706-A | CARBAMYLATION, NEUTRALIZATION | PPG INDUSTRIES, INC. (US) | 1981-10-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CASP1 3384/4885MME 613/4885ECE1 896/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CASP1 3384/4885MME 613/4885ECE1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.